Yichang IPO aims to woo choosy investors

The Chinese drug maker hopes to convince investors who have been highly selective in healthcare assets this year.

Yichang IPO aims to woo choosy investors

Chinese drug manufacturer Yichang HEC Changjiang Pharmaceutical launched an initial public offering in Hong Kong on Monday at a time investors are highly selective in taking on healthcare-related assets.  

A termsheet seen by FinanceAsia shows the company is selling 90.1 million shares, or 20% of its enlarged share capital, at an indicative price range of HK$13.70-HK$18.50 per share at the base size. There is a standard 15% greenshoe option.


FinanceAsia has updated its subscription model. Registered readers now have the opportunity to read five articles from our award-winning website for free. Please subscribe for unlimited access.

Click for more on: yichang hec | cicc | health | ipo | china | hong kong

Print Edition

FinanceAsia Print Edition